JP2011513315A - 組合せ抗がん剤 - Google Patents
組合せ抗がん剤 Download PDFInfo
- Publication number
- JP2011513315A JP2011513315A JP2010548807A JP2010548807A JP2011513315A JP 2011513315 A JP2011513315 A JP 2011513315A JP 2010548807 A JP2010548807 A JP 2010548807A JP 2010548807 A JP2010548807 A JP 2010548807A JP 2011513315 A JP2011513315 A JP 2011513315A
- Authority
- JP
- Japan
- Prior art keywords
- lucanton
- antimetabolite
- administered
- therapeutically effective
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
【選択図】 なし
Description
[0001]本出願は、本明細書中にその開示がそのまま援用される、2008年2月29日出願の米国仮特許出願第61/032,831号の恩典を請求する。
[0049]方法:CD−1ヌードマウスの群の皮下に、ヒトH460非小細胞肺癌細胞を異種移植した。処置は、腫瘍成長が約130mm3に達した時に開始した。処置は、4日毎に1回の頻度で7回投与し、そしてビヒクル;200mg/kgで腹腔内投与されるペメトレキセド;80mg/kgで経口投与されるルカントン;および同用量でのペメトレキセドおよびルカントンの組合せを包含した。腫瘍成長および体重変化を、28日間追跡した。
[0051]上の実施例1による方法は、1日2回投与、すなわち、朝に1回および晩に1回に用いることができる。その手順を、下の表1に要約する。
Claims (20)
- 哺乳動物の癌を処置する方法であって、
ルカントンを当該哺乳動物に投与し;そして
少なくとも一つの代謝拮抗物質を当該哺乳動物に投与すること
を含み、ここにおいて、当該ルカントンおよび当該少なくとも一つの代謝拮抗物質を、治療的有効量で投与する方法。 - 前記少なくとも一つの代謝拮抗物質が、葉酸代謝拮抗物質である、請求項1に記載の方法。
- 前記少なくとも一つの代謝拮抗物質が、ペメトレキセドである、請求項1に記載の方法。
- 前記ルカントンおよび前記少なくとも一つの代謝拮抗物質を、同時に投与する、請求項1に記載の方法。
- 前記ルカントンおよび前記少なくとも一つの代謝拮抗物質を、逐次的に投与する、請求項1に記載の方法。
- 前記ルカントンおよび前記少なくとも一つの代謝拮抗物質を、互いの約3時間以内に投与する、請求項5に記載の方法。
- 前記ルカントンおよび前記少なくとも一つの代謝拮抗物質を、互いの約2時間以内に投与する、請求項5に記載の方法。
- 前記ルカントンおよび前記少なくとも一つの代謝拮抗物質を、互いの約1時間以内に投与する、請求項5に記載の方法。
- 前記癌が、肺癌である、請求項1に記載の方法。
- 前記肺癌が、非小細胞肺癌である、請求項9に記載の方法。
- 前記治療的有効量のルカントンおよび前記治療的有効量の少なくとも一つの代謝拮抗物質を、1日1回投与するか、または1日2回以上の投与に分割する、請求項1に記載の方法。
- 前記1日2回以上の投与が、1日2回の投与である、請求項1に記載の方法。
- 前記ルカントンおよび前記少なくとも一つの代謝拮抗物質を、経口投与する、請求項1に記載の方法。
- 前記ルカントンおよび前記少なくとも一つの代謝拮抗物質を、非経口投与する、請求項1に記載の方法。
- 前記ルカントンおよび前記少なくとも一つの代謝拮抗物質を、カプセル剤または錠剤の形で投与する、請求項1に記載の方法。
- 前記ルカントンおよび前記少なくとも一つの代謝拮抗物質を、一つまたはそれを超えるサイクルで投与する、請求項1に記載の方法。
- 前記の一つのサイクルが、4日毎での7回を含む、請求項16に記載の方法。
- 放射線療法、ホルモン療法または免疫療法を施すことを更に含む、請求項1に記載の方法。
- 治療的有効量のルカントンおよび少なくとも一つの代謝拮抗物質、および薬学的に許容しうる担体を含む、医薬組成物。
- 治療的有効量のルカントンおよび薬学的に許容しうる担体を含む医薬組成物、および
治療的有効量の少なくとも一つの代謝拮抗物質および薬学的に許容しうる担体を含む医薬組成物
を含む医薬キット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3283108P | 2008-02-29 | 2008-02-29 | |
US61/032,831 | 2008-02-29 | ||
PCT/US2009/034629 WO2009108573A1 (en) | 2008-02-29 | 2009-02-20 | Combination anti-cancer agents |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2011513315A true JP2011513315A (ja) | 2011-04-28 |
JP2011513315A5 JP2011513315A5 (ja) | 2012-04-05 |
JP5590560B2 JP5590560B2 (ja) | 2014-09-17 |
Family
ID=40566524
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010548807A Expired - Fee Related JP5590560B2 (ja) | 2008-02-29 | 2009-02-20 | 組合せ抗がん剤 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20090221615A1 (ja) |
EP (1) | EP2257285A1 (ja) |
JP (1) | JP5590560B2 (ja) |
KR (1) | KR20100126453A (ja) |
CN (1) | CN102014895A (ja) |
AU (1) | AU2009219464B2 (ja) |
BR (1) | BRPI0908398A2 (ja) |
CA (1) | CA2717100A1 (ja) |
IL (1) | IL207859A (ja) |
MX (1) | MX2010009502A (ja) |
RU (1) | RU2516027C2 (ja) |
WO (1) | WO2009108573A1 (ja) |
ZA (1) | ZA201006123B (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2727273T3 (es) * | 2010-03-08 | 2019-10-15 | Spectrum Pharmaceuticals Inc | Terapias inhibidoras de la autofagia basadas en tioxantina para tratar el cáncer |
EP2425830A1 (en) | 2010-09-03 | 2012-03-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synergistic drug combination for the treatment of cancer |
WO2023114245A2 (en) * | 2021-12-14 | 2023-06-22 | Radin Daniel Pierce | Compositions and methods for treating cancers of the central nervous system (cns), including glioblastoma and chemoresistant cns tumors, and related compositions and methods for inhibiting and eliminating cns cancer stem cells |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007071970A2 (en) * | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Combination of azd2171 and pemetrexed |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1021204B1 (en) * | 1997-09-26 | 2005-12-28 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
US6391911B1 (en) * | 1999-02-26 | 2002-05-21 | Robert E. Bases | Coadministration of lucanthone and radiation for treatment of cancer |
US20080269261A1 (en) * | 2005-12-22 | 2008-10-30 | Anderson Joseph Ryan | Combination of Zd6474 and Pemetrexed |
-
2009
- 2009-02-19 US US12/389,318 patent/US20090221615A1/en not_active Abandoned
- 2009-02-20 MX MX2010009502A patent/MX2010009502A/es active IP Right Grant
- 2009-02-20 RU RU2010139840/14A patent/RU2516027C2/ru not_active IP Right Cessation
- 2009-02-20 CN CN2009801154644A patent/CN102014895A/zh active Pending
- 2009-02-20 BR BRPI0908398-7A patent/BRPI0908398A2/pt not_active Application Discontinuation
- 2009-02-20 CA CA2717100A patent/CA2717100A1/en not_active Abandoned
- 2009-02-20 KR KR1020107021665A patent/KR20100126453A/ko active IP Right Grant
- 2009-02-20 WO PCT/US2009/034629 patent/WO2009108573A1/en active Application Filing
- 2009-02-20 EP EP09714301A patent/EP2257285A1/en not_active Withdrawn
- 2009-02-20 JP JP2010548807A patent/JP5590560B2/ja not_active Expired - Fee Related
- 2009-02-20 AU AU2009219464A patent/AU2009219464B2/en not_active Ceased
-
2010
- 2010-08-27 ZA ZA2010/06123A patent/ZA201006123B/en unknown
- 2010-08-29 IL IL207859A patent/IL207859A/en not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007071970A2 (en) * | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Combination of azd2171 and pemetrexed |
Non-Patent Citations (3)
Title |
---|
JPN5011007367; FOSSELLA F V: 'PEMETREXED FOR TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER' SEMINARS IN ONCOLOGY V31 N1 SUPPL 01, 20040201, P100-105 * |
JPN6013042468; Benjamin Prescott: 'New salts of lucanthone as potential anticancer agents' J. Med. Chem. 11 (1), 1968, 156-8 * |
JPN6013042471; Lawrence S. Koons, et al.: 'Potentiation of mitomycin c by lucanthone-hcl (miracil d) in transplanted c3h mammary tumors' Mitomycin C: Curr. Status New Dev. , 1979, 69-75 * |
Also Published As
Publication number | Publication date |
---|---|
CA2717100A1 (en) | 2009-09-03 |
EP2257285A1 (en) | 2010-12-08 |
KR20100126453A (ko) | 2010-12-01 |
WO2009108573A1 (en) | 2009-09-03 |
CN102014895A (zh) | 2011-04-13 |
IL207859A (en) | 2015-09-24 |
IL207859A0 (en) | 2010-12-30 |
RU2010139840A (ru) | 2012-04-10 |
RU2516027C2 (ru) | 2014-05-20 |
ZA201006123B (en) | 2011-05-25 |
MX2010009502A (es) | 2010-11-10 |
JP5590560B2 (ja) | 2014-09-17 |
AU2009219464B2 (en) | 2015-04-09 |
BRPI0908398A2 (pt) | 2015-08-11 |
US20090221615A1 (en) | 2009-09-03 |
AU2009219464A1 (en) | 2009-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3148336B1 (en) | Eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer | |
US20090035292A1 (en) | Use of phosphatases to treat neuroblastomas and medulloblastomas | |
CN110996927A (zh) | 复发性胶质母细胞瘤(rgbm)的治疗方法 | |
JP5590560B2 (ja) | 組合せ抗がん剤 | |
MXPA06014477A (es) | Agente antitumor, fortificador de efecto antitumor y metodo de terapia para cancer. | |
CN106389437A (zh) | 低剂量西地那非作为抗肿瘤药物的应用 | |
US20230038138A1 (en) | Combination therapy for treating cancer | |
US11419862B2 (en) | Quinoline derivative for treatment of nasopharyngeal carcinoma | |
CN115190800A (zh) | 一种brd4抑制剂的用途 | |
CN111821302A (zh) | 用于联合治疗软骨肉瘤的喹啉类化合物 | |
CN106999485B (zh) | 抗肺鳞癌的喹啉衍生物 | |
CN111939165B (zh) | 非天然人参皂苷3β-O-Glc-DM在制备预防或治疗胶质母细胞瘤药物中的应用 | |
US11648235B1 (en) | Treatment of glioblastoma | |
WO2022171064A1 (zh) | 烟酰胺及含有其的组合物的制药用途 | |
CN113274394B (zh) | 一种治疗酪氨酸激酶抑制剂耐药的非小细胞肺癌的药物组合物 | |
EP4335442A1 (en) | Use of adenosine diphosphate ribose as adjuvant therapy for radiation and/or anticancer therapy | |
CN107137406B (zh) | 一种Hedgehog信号通路抑制剂在制备治疗EGFR过度表达的癌症的药物中的用途 | |
Arena et al. | Stomatitis and EGFR-tyrosine kinase inhibitors: a review of current literature in 4353 patients | |
CN115463143A (zh) | 非天然人参皂苷3β,12β-Di-O-Glc-PPD治疗脑瘤的用途 | |
CN115721722A (zh) | 一种治疗egfr-tki耐药的非小细胞肺癌的药物组合物 | |
US20240165120A1 (en) | Treating cancer in patient having co-occurring genetic alteration in fgfr2 and a cancer driver gene | |
CN113747898A (zh) | 用于联合治疗软组织肉瘤的喹啉衍生物 | |
CN112105361A (zh) | 用于治疗非小细胞肺癌的喹啉衍生物 | |
CA2430489A1 (en) | Methods for contemporaneous administration of levamisole and 5-fluorouracil |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120213 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120213 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130827 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131126 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20131126 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131216 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140416 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140521 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140612 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140708 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140723 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5590560 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |